Profile data is unavailable for this security.
About the company
Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
- Revenue in SEK (TTM)177.92m
- Net income in SEK7.70m
- Incorporated2012
- Employees78.00
- LocationMagle Chemoswed Holding ABAgneslundsvagen 27MALMO 212 15SwedenSWE
- Phone+46 40383300
More ▼
Mergers & acquisitions
| Acquired company | MAGLE:STO since announced | Transaction value |
|---|---|---|
| Amniotics AB (publ) | 17.36% | 1.05m |
Data delayed at least 15 minutes, as of Oct 11 2024 17:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lipum AB (publ) | 0.00 | -44.17m | 271.52m | 5.00 | -- | 5.49 | -- | -- | -3.77 | -3.77 | 0.00 | 2.33 | 0.00 | -- | -- | 0.00 | -124.17 | -127.85 | -147.77 | -184.50 | -- | -- | -- | -293,228.70 | -- | -423.66 | 0.0344 | -- | -- | -- | 2.38 | -- | -- | -- |
| Dicot Pharma AB | 233.09k | -50.94m | 299.90m | 3.00 | -- | 10.74 | -- | 1,286.64 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
| Arctic Bioscience AS | 30.36m | -46.74m | 306.42m | 20.00 | -- | 1.35 | -- | 10.09 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Magle Chemoswed Holding AB | 177.92m | 7.70m | 396.55m | 78.00 | 49.68 | 2.38 | 18.65 | 2.23 | 0.7125 | 0.7125 | 16.47 | 14.84 | 0.628 | 0.5621 | 10.52 | 2,281,000.00 | 2.72 | 2.52 | 3.59 | 3.52 | 87.81 | 85.67 | 4.33 | 3.92 | 0.6117 | 3.42 | 0.3208 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -142.27m | 426.99m | 9.00 | -- | 1.87 | -- | -- | -10.57 | -10.57 | 0.00 | 17.57 | 0.00 | -- | -- | 0.00 | -46.35 | -16.11 | -54.97 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -34.70m | 434.48m | 3.00 | -- | 4.26 | -- | -- | -0.2164 | -0.2164 | 0.00 | 0.6309 | 0.00 | -- | -- | 0.00 | -24.29 | -66.73 | -28.91 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Enzymatica AB (publ) | 44.95m | -55.95m | 441.78m | 17.00 | -- | 4.86 | -- | 9.83 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | -- | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Orexo AB | 615.40m | -96.70m | 485.95m | 112.00 | -- | 19.93 | -- | 0.7897 | -2.81 | -2.81 | 17.86 | 0.7025 | 0.7239 | 1.06 | 2.42 | 5,305,173.00 | -11.38 | -6.41 | -17.08 | -9.99 | 88.22 | 86.76 | -15.71 | -11.83 | 1.51 | -0.5276 | 0.9612 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Navamedic ASA | 525.16m | 23.81m | 530.79m | 45.00 | 22.30 | 2.22 | 13.78 | 1.01 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
| Moberg Pharma AB (publ) | 4.93m | -22.75m | 555.41m | 9.00 | -- | 0.5723 | -- | 112.68 | -0.9608 | -0.9608 | 0.1936 | 20.27 | 0.0065 | -- | 0.4949 | -- | -3.02 | -- | -3.12 | -- | 65.19 | -- | -461.64 | -- | 12.32 | -- | 0.0043 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Data as of Oct 11 2024. Currency figures normalised to Magle Chemoswed Holding AB's reporting currency: Swedish Krona SEK
